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MicroRNAs are small RNA molecules that regulate messenger RNA (mRNA)
expression. MicroRNA 122 (miR-122) is specifically expressed and highly
abundant in the human liver. We show that the sequestration of miR-122 in
liver cells results in marked loss of autonomously replicating hepatitis C viral
RNAs. A genetic interaction between miR-122 and the 5¶ noncoding region of
the viral genome was revealed by mutational analyses of the predicted
microRNA binding site and ectopic expression of miR-122 molecules containing
compensatory mutations. Studies with replication-defective RNAs suggested
that miR-122 did not detectably affect mRNA translation or RNA stability.
Therefore, miR-122 is likely to facilitate replication of the viral RNA, suggesting
that miR-122 may present a target for antiviral intervention.
MicroRNAs (miRNAs) are a class of small
RNA molecules, È21 to 22 nucleotides (nt) in
length, that have been detected in many plant
and animal species (1). Even certain animal
viral RNA genomes encode miRNAs (2–4).
Cloning efforts and computational predictions
have indicated that there are È800 miRNA-
encoding genes in humans (5), which together
regulate more than 5300 genes (6, 7). Inter-
action of miRNAs with target mRNAs results
in mRNA cleavage if the bound miRNA
engages in perfect base complementarity with
its target (8, 9). However, in a few cases,
imperfect base complementarity between a
miRNA and target mRNA leads to transla-
tional repression (10–15). In all of these ex-
amples, the miRNA interacts with sequences
within the 3¶ noncoding region (NCR) of the
target mRNA.
Certain miRNAs are expressed ubiquitous-
ly, whereas others are expressed in a highly
tissue-specific manner (16, 17). MiR-122 is
specifically expressed in the liver, where it
constitutes 70% of the total miRNA population
(16, 18). To examine the role of miR-122 in
regulating mRNA function, we first monitored
the expression of miR-122 in liver tissue and
liver cell lines. MiR-122 was detected in
mouse and human liver, in cultured human
Huh7 and mouse Hepa 1-6 liver cells, but not
in human cervical carcinoma-derived HeLa
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Fig. 1. miR-122 is expressed in Huh7 cells and has two predicted
binding sites in the HCV genome. (A) Northern blot analysis of miR-
122 expression in total RNA extracted from mouse and human liver,
human HeLa and HepG2 cells, naı¨ve replicon and cured human Huh7
cells, and mouse Hepa1-6 cells. Expression of U6 small nuclear (sn) RNA was used as a loading control. (B) Sequence of miR-122 with the seed
sequences surrounded by a box. (C and D) Secondary structure of the (C) 3¶ and (D) 5¶ noncoding regions of the HCV genotype 1a strain H77c, with
predicted miR-122 binding sites indicated. The seed matches are enclosed in boxes. SL, stem-loop; UTR, untranslated region.
R E P O R T S
www.sciencemag.org SCIENCE VOL 309 2 SEPTEMBER 2005 1577
o
n
 M
ay 3, 2018
 
http://science.sciencem
ag.org/
D
ow
nloaded from
 
cells or even in human liver-derived HepG2
cells (Fig. 1A).
Hepatitis C virus (HCV) is a hepatotropic,
positive-stranded RNA virus belonging to the
family Flaviviridae; it is a major cause for
chronic liver disease with an estimated 170
million people infected (19). Although both
Huh7 and HepG2 cells are derived from human
hepatocytes, HCV RNA constructs can only
replicate in Huh7 cells. To explore whether this
could be related to the presence of miR-122
in permissive Huh7 cells, we inspected the
9600-nt, positive-strand, viral RNA genome for
potential miR-122 binding sites that fulfill the
rules for a successful miRNA-target mRNA
interaction. We searched for sequences in the
viral mRNA that could engage in Watson and
Crick base pairing with nucleotides 2 through
8, the Bseed sequence[ of miR-122 (6, 20), and
we noted two predicted binding sites for miR-
122 (Fig. 1B) in the viral NCRs. One is located
within the viral 3¶ NCR of the genotype 1a
(Fig. 1C). Although this sequence is in the
Bvariable region[ of the 3¶ NCR, the seed
match sequence itself is highly conserved
among the six HCV genotypes (table S1).
The second miR-122 binding site is also
conserved and is located within the 5¶ NCR,
only 21 nt from the 5¶ end of the viral genome
(Fig. 1D). With the exception of genotype 2,
the putative seed match sequence is flanked by
adenosines (table S1), indicative of a high
confidence miRNA-binding site (6).
To determine whether miR-122 regulates
HCV gene expression, we tested whether its
inactivation would alter the abundance of an
autonomously replicating, dicistronic HCV
RNA replicon. Huh7 cells stably expressing the
genotype 1b strain HCV-N replicon NNeo/C-5B
were used (Fig. 2A) (21). To inactivate miR-
122 in this cell line, NNeo/C-5B cells were
transfected with a 2¶-O-methylated RNA oligo-
nucleotide (122-2¶OMe) with exact comple-
mentarity to miR-122. Such oligonucleotides
have been shown to sequester miRNAs (22, 23).
As a control for functional inactivation of
miR-122, we monitored the expression of
enhanced green fluorescent protein (eGFP)
sensor mRNAs that contained sequences com-
plementary to miR-122 in their 3¶ NCR (eGFP-
122). Because of its complete complementarity,
miR-122 should lead to the nucleolytic degra-
dation of the eGFP mRNAs. Indeed, little full-
length eGFP-122 RNA was detected in cells
transfected with plasmids encoding eGFP-122
(Fig. 2A, lane 3), although a similar RNA that
contained sites complementary to the brain-
specific miR-124 was expressed at high levels
(Fig. 2A, lane 2). Upon transfection with 122-
2¶OMe, the amount of eGFP-122 RNA
markedly increased (Fig. 2A, lane 4), whereas
a randomized oligomer (Rand-2¶OMe, lane 5)
and an oligomer complementary to miRNA
Fig. 2. Sequestration of miR-122 reduces HCV RNA and protein abundance in
replicon cells. (A) Northern blot analysis of HCV, eGFP, and actin RNA in the
NNeo/C-5B replicon cell line. In these replicon RNAs (21), the HCV internal
ribosome entry site (IRES) directs the synthesis of the neomycin resistance gene
product, and the encephalomyocarditis viral IRES (EMCV) directs the synthesis
of the structural and nonstructural (NS) proteins of the HCV-N 1b strain. The
eGFP sensor plasmids and 2¶-O-methylated oligonucleotides were introduced
into cells by lipofectamine 2000–mediated transfection, and total RNA was
extracted 48 hours later. Quantitation of the HCV-actin mRNA ratios from
three independent Northern blot experiments and the standard deviations are
shown. (B) Western blot showing levels of HCV core protein, eGFP, and actin
48 hours post-transfection with the indicated eGFP sensor plasmids and 2¶-O-
methylated oligomers. (C) Northern analysis of HCV, eGFP, and actin RNA in
Huh7 cells containing the genome-length genotype 1a H77c RNA and
transfected with eGFP-122 and 122-2¶OMe. Quantitation of the HCV-actin
mRNA ratios from three independent Northern blot experiments and the
standard deviations are shown. The locations of cell culture–acquired adaptive
mutations in the viral RNA are indicated by asterisks in the top diagram.
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let-7a (let7-2¶OMe) had no effect (Fig. 2A,
lane 6). The level of HCV viral replicon RNA
was specifically reduced by È80% when miR-
122 was inactivated (Fig. 2A, lanes 4 and 7).
Reduced mRNA abundance resulted in a de-
crease in HCV protein expression in cells
transfected with the 122-2¶OMe oligomer,
whereas the level of eGFP protein increased
under this experimental condition (Fig. 2B,
lane 3).
To determine whether miR-122 would sim-
ilarly affect RNA accumulation in cells newly
transfected with replication-competent HCV
RNA, RNA transcripts were synthesized from
a cDNA that encodes the full-length genotype
1a strain H77c genome. Five adaptive muta-
tions in the cDNA (Fig. 2C, top) promote ef-
ficient RNA replication in Huh7 cells (24).
Introduction of these RNAs into Huh7 cells
led to accumulation of viral RNA in the pres-
ence of endogenous miR-122 (Fig. 2C, lanes 1
and 2); in contrast, viral RNA failed to ac-
cumulate when miR-122 was sequestered by
122-2¶OMe oligomers (Fig. 2C, lane 3).
Furthermore, the 122-2¶OMe oligomer did not
affect total protein synthesis in transfected
cells, excluding the possibility that the 122-
2¶OMe oligomer induced antiviral effects (fig.
S1). Thus, miR-122 is required to maintain the
abundance of both genotypes 1a and 1b RNA,
both in a stable cell line supporting autono-
mous replication of a dicistronic replicon and
upon direct transfection of minimally modified
genomic RNA.
To investigate whether the putative miR-122
binding sites are required for the miR-122 effects
on RNA abundance, we introduced mutations
into the H77c cDNA. Transfection of H77c
RNAs containing a 4-nt substitution mutation,
m3¶, in the predicted seed match in the 3¶ NCR
(Fig. 3A, left) did not diminish RNA accumu-
lation (Fig. 3B, lane 2). In contrast, RNAs that
contained single-nucleotide substitution muta-
tions at the p3 and p6 positions in the seed
match in the 5¶ NCR or double mutations at
the p3-p4 position failed to accumulate (Fig.
3B, lanes 4, 9, and 11). However, RNAs with
mutations at p1 accumulated to similar levels
(Fig. 3B, lane 8) as wild-type RNA (lane 6),
supporting the idea that p1 does not contribute
to formation of microRNA-mRNA complexes
(6). These findings suggest that failure to
recruit miR-122 to the HCV 5¶ NCR caused
loss of viral RNA or that the mutations af-
fected translation, stability, or replication of
HCV RNA.
If mutations in the HCV 5¶ NCR reduced
RNA accumulation because of poor binding of
miR-122, ectopic expression of miR-122 RNAs
that contain base complementary mutations
should restore mutant microRNA–mutant RNA
complexes. Ectopic expression of wild-type
miR-122 RNAs did not rescue p3, p6, or p3-4
mutated viral RNAs (Fig. 3B, lanes 4, 9, and
11) but did enhance the abundance of wild-type
viral RNAs (lane 7) and replicon RNAs (fig.
S2). This demonstrated that the introduced
miR-122 RNAs entered the cellular machinery
as functional miRNA molecules and that the
Fig. 3. The predicted
miR-122 binding site in
the 5¶ noncoding region
of HCV is required for
viral RNA maintenance
and directly interacts
with miR-122. (A) Posi-
tion of the mutations
introduced into the
H77c full-length RNA.
The locations of a 4-nt
substitution mutation in
the seed match in the 3¶
noncoding region (m3¶)
and single- or double-
substitution mutations
in the 5¶ noncoding
region seed match (p1,
p3, p6, and p3-4) are
shown. The mutated
nucleotides are enclosed
in boxes. (B) RNA was
synthesized by in vitro
transcription and intro-
duced into Huh7 cells
by electroporation, and
HCV RNA levels were
determined by Northern
blotting 5 days later.
Levels of actin mRNAs
were determined as
loading controls. Cells
were transfected with synthetic duplexes corresponding to wild-type miR-122 (wt) or miR-122
with mutations in the seed complementary to the seed match mutations, with the opposite strand
of the duplex based on the miR-122 precursor hairpin. The duplexes were introduced into cells 1 day
before electroporation with wild-type H77c RNAs or mutant RNAs, and again at 1 and 3 days post-
electroporation. Total RNA was harvested 5 days post-electroporation, and HCV and actin RNA
levels were determined by Northern blotting. (C) Quantitation of the HCV-actin mRNA ratios from
three independent Northern blot experiments and the standard deviations are shown.
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endogenous pool of miR-122 that mediates the
accumulation of viral RNA is limiting. In
contrast, expression of mutated p3, p6, and
p3-4 miR-122 duplexes allowed accumulation of
mutated viral RNAs (Fig. 3B, lanes 5, 10, and
12, and Fig. 3C), arguing for a genetic
interaction between miR-122 and the 5¶ NCR
of the HCV genome. Furthermore, the rescue
of mutated viral RNAs by miR-122 RNAs
carrying complementary mutations provides
evidence for a direct HCV RNA–miR-122 in-
teraction, rather than an indirect effect through
another miR-122 target.
It has been speculated that microRNAs
reduce the accumulation of proteins encoded
by target mRNAs by modulating translational
efficiency of the mRNAs (1). Thus, we ex-
amined whether miR-122 modulates transla-
tion of HCV RNA, which occurs by an internal
ribosome entry mechanism (25–27). We mon-
itored the production of HCV core protein
from transfected replicating and nonreplicating
viral RNAs, containing or lacking miR-122
binding sites. Slightly greater amounts of core
protein accumulated by 20 hours after transfec-
tion with wild-type (Fig. 4A, lane 1) versus p3-
mutant RNA (Fig. 4A, lane 2). This difference
is likely due to early replication of wild-type
RNA. However, we were unable to detect full-
length viral RNA by Northern analysis at
this time point. To examine production of
core protein from input RNAs in the absence
of replication, we monitored translation of
replication-defective viral RNAs. Both wild-
type (Fig. 4A, lane 3) and p3-mutant (lane 4)
RNAs containing a replication-lethal muta-
tion in the viral RNA polymerase (GDD to
AAG) produced similar amounts of core pro-
tein. These data may indicate that p3-mutant
RNAs are less stable yet more efficiently
translated than wild-type RNAs. An alternative
interpretation suggests that mutant and wild-
type RNAs display similar stabilities and
translational efficiencies at 20 hours after
transfection.
To distinguish between these two pos-
sibilities, we monitored the abundance of
wild-type and mutated genotype 1b replicon
RNAs derived from the strain HCV-N after their
transfection into En5-3 cells. These replicon
RNAs (Fig. 4C) express the human immuno-
deficiency virus tat protein and induce secretion
of alkaline phosphatase (SEAP) in these cells in
a manner that quantitatively reflects the intra-
cellular abundance of the replicon RNAs (28).
The mutant p3 replicon failed to accumulate
over time after transfection compared to the
wild-type replicon (Fig. 4B). Furthermore, the
SEAP secretion profile of the p3 replicon
mirrored that of cells transfected with the
replication-deficient DGDD mutant, arguing
that translation and stability of mutant p3-
replicon RNAs are not affected by the p3
mutation (Fig. 4B). Taken together, these
findings suggest that mutation of the seed match
sequence for miR-122 in the HCV 5¶ NCR does
not primarily affect RNA translation or stability,
at least at early times after RNA transfection, and
likely affects viral RNA replication. In the
absence of miR-122, core-encoding sequences
have been reported to interact with nucleotides
24 to 38 in the viral 5¶ NCR, resulting in
translational inhibition in dicistronic mRNAs
(29). However, mutations encompassing the
miR-122 binding site have been shown to
primarily affect replication of replicon RNAs
(30) in cells expressing miR-122, suggesting that
miR-122 may aid in RNA folding or RNA
sequestration in replication complexes.
Although two plant miRNAs interact with
the 5¶ NCR of their target mRNAs (31), this has
not been observed for animal miRNAs (6).
Thus, our finding that the HCV genome recruits
miR-122 to its 5¶ end raises the question of
whether 5¶ NCRs in other viral or host cell
mRNAs can also be targeted by microRNAs
and whether such interactions regulate mRNA
translation, mRNA turnover, or possibly RNA
localization. HCV RNA can replicate in non-
hepatic cells (32–34), raising the question of
whether the role of miR-122 in regulating HCV
gene expression is liver-specific. What are the
natural targets for miR-122 in the liver, and is
their expression affected by HCV infection?
Finally, current therapies against HCV are
frequently ineffective; thus, there is a need to
search for alternative antiviral targets. Seques-
tration of host-encoded miR-122 could provide
a possible antiviral tool against a rapidly
evolving viral genome.
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Recombination Regulation by
Transcription-Induced Cohesin
Dissociation in rDNA Repeats
Takehiko Kobayashi1,2* and Austen R. D. Ganley1
Organisms maintain ribosomal RNA gene repeats (rDNA) at stable copy num-
bers by recombination; the loss of repeats results in gene amplification. Here we
report a mechanism of amplification regulation. We show that amplification is
dependent on transcription from a noncoding bidirectional promoter (E-pro)
within the rDNA spacer. E-pro transcription stimulates the dissociation of
cohesin, a DNA binding protein complex that suppresses sister-chromatid–based
changes in rDNA copy number. This transcription is regulated by the silencing
gene, SIR2, and by copy number. Transcription-induced cohesin dissociation
may be a general mechanism of recombination regulation.
In most organisms, recombination is neces-
sary for DNA repair, chromosome segrega-
tion, and the rescue of stalled replication
forks. If not properly regulated, however, re-
combination can lead to genomic instability
(1) and can be toxic to cells (2). It is not clear
how cells maintain only the positive effects
of recombination.
In repeated-gene families, such as the
ribosomal RNA (rRNA) gene repeats (rDNA),
recombination helps maintain copy number
(3) and the evolutionary stability of the
repeats (4). The number of rDNA copies is
tightly regulated; if repeats are deleted or
inserted, copy number is quickly restored to
that of the wild type (5, 6). One way that
copy number is maintained is by gene am-
plification after deletional recombination.
In the yeast Saccharomyces cerevisiae, this
amplification is dependent on the replication-
fork blocking protein, FOB1, and a È520–
base pair (bp) cis-acting factor called EXP,
which is found in the rDNA intergenic
spacer (IGS) (Fig. 1A) (6, 7). In a recent
Saccharomyces species phylogenetic foot-
printing study, we found a highly conserved
sequence that corresponds to a previously
identified bidirectional RNA polymerase
II (pol II) promoter (8) in EXP (9). This
EXP promoter (named E-pro) does not
appear to be associated with any coding
function, and its position and conservation
suggested it might play a role in rDNA
amplification.
To determine whether E-pro is involved in
rDNA amplification, we replaced it with
galactose-inducible pol II promoters (uni-
directional GAL7 and bidirectional GAL1/10
promoters) (fig. S1) in an S. cerevisiae strain
containing only two rDNA copies (two-copy
strain), and we observed the effects on
amplification. Reintroduction of a plasmid-
borne FOB1 gene into the two-copy strain
stimulated rDNA amplification, and the
resulting rDNA copy-number increase can
be visualized by an increase in the size of
chromosome XII (chr XII) by using pulsed-
field gel electrophoresis Econtour-clamped
homogeneous electric field (CHEF)^ (7). The
deletion of E-pro abolished amplification abil-
ity (Fig. 1, B and C), and when E-pro was
replaced with the GAL7 promoter in either di-
rection, amplification ability was not rescued.
However, when E-pro was replaced with the
bidirectional GAL1/10 promoter (GAL1/10
strain), the introduction of FOB1 resulted in
amplification.
To confirm that amplification depends on
E-pro transcription, we changed the carbon
source from galactose to glucose to inhibit
transcription in the GAL1/10 strain. The size
of chr XII continued to increase in galactose-
grown cells, but did not increase in glucose-
grown cells over 150 generations (Fig. 1D).
Furthermore, the chr XII bands of cells
grown in glucose were sharp, indicating the
inhibition of rDNA recombination (6). To
investigate whether read-through transcrip-
tion or another function of E-pro is required
for amplification, we blocked each direction
of GAL1/10 transcription by using a tran-
scriptional terminator. Blockage in either
direction resulted in the loss of amplification
ability (Fig. 1D). Therefore, bidirectional E-
pro transcription is essential for rDNA
amplification.
How can transcription from E-pro trigger
recombination and hence amplification? One
way is through cohesin association. Cohesin
is a multifunctional protein complex involved
in chromatin structure (10), and its localiza-
tion is inversely correlated with transcrip-
tion, suggesting that transcription disrupts
cohesin association (11, 12). Cohesin asso-
ciation is thought to hold chromatids in place,
leading to equal (versus unequal) sister-
chromatid recombination and thereby pre-
venting changes in copy number after the
formation of double-strand breaks (DSBs)
(13). Thus, E-pro transcription may result in
cohesin dissociation, allowing a change in
copy number. Chromatin immunoprecipi-
tation (ChIP) assays were performed with a
GAL1/10 strain carrying hemagglutinin (HA)
epitope–tagged Mcd1p (a cohesin complex
component) in conjunction with seven rDNA
primer combinations (Fig. 2). In the wild-
type strain grown in both glucose and galac-
tose, the cohesin associating region (CAR)
gave the strongest signal of cohesin asso-
ciation, as found previously (13, 14), and
the pattern in the galactose-grown GAL1/10
strain was similar. However, when grown in
glucose, the GAL1/10 strain showed much
stronger cohesin association throughout the
IGS. Thus, the repression of E-pro tran-
scription leads to increases in cohesin asso-
ciation on both sides of E-pro, not just in
CAR. This increase is consistent with bidi-
rectional transcription dissociating cohesin
in both IGS1 and 2, and it suggests that
unidirectional transcription leaves cohesin
association on the opposite side, inhibiting
unequal sister-chromatid recombination. We
also tested the effect of a cohesin mutation,
smc1-2 (15), in the GAL1/10 strain, and we
confirmed that the amplification rate was in-
creased (fig. S2).
The silencing gene SIR2 suppresses rDNA
copy-number change through effects on
cohesin association, because SIR2 loss results
in the loss of cohesin association in the IGS
(13). SIR2 represses pol II–transcribed genes
integrated in the rDNA (16, 17). We therefore
speculated that SIR2 regulates recombination
by repressing E-pro transcription. To test this,
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